Dr. Aaron (Ron) Weitzman brings to Biosion over 20 years of Oncology clinical development experience in the biotech and pharmaceutical industries. Dr. Weitzman joined Biosion as a medical oncologist consultant whose consulting work over the last 6 years has focused on early oncology drug development. Prior to establishing his own consulting company, Dr. Weitzman worked with Exelixis where he served as Vice President of Clinical Development where he oversaw the development of cabozantinib spanning the period from its initial phase 1 study to subsequent approvals. Prior to Exelixis, Ron was Group Director at Genentech overseeing Avastin’s development in NSCLC and GBM. Ron has also worked with Novartis Pharmaceuticals and Eli Lilly company before that. 

Dr. Weitzman has an MD degree from The University of Western Ontario and completed an internal medicine residency at The Mount Sinai Hospital in NYC and a medical oncology fellowship at Columbia Presbyterian Medical Center.